title: Does ponatinib cross the blood-brain barrier?
authors.affiliation: Department of Haematology/Oncology, National University Cancer Institute Singapore (NCIS), Singapore.
authors.forename: Muhammad B
authors.initials: MB
authors.lastname: Abid
authors.affiliation: Department of Haematology/Oncology, National University Cancer Institute Singapore (NCIS), Singapore.
authors.forename: Sanjay
authors.initials: S
authors.lastname: De Mel
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000378:metabolism*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D009154:Mutation; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011724:Pyridazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl
keywords: Ph+ALL; T315I mutation; ponatinib; tyrosine kinase inhibitor